GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (TSE:4565) » Definitions » Capex-to-Operating-Income

Nxera Pharma Co (TSE:4565) Capex-to-Operating-Income : 0.00 (As of Jun. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Nxera Pharma Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Nxera Pharma Co's Capital Expenditure for the three months ended in Jun. 2024 was 円-56.00 Mil. Its Operating Income for the three months ended in Jun. 2024 was 円-578.00 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Nxera Pharma Co Capex-to-Operating-Income Historical Data

The historical data trend for Nxera Pharma Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nxera Pharma Co Capex-to-Operating-Income Chart

Nxera Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.73 0.11 0.05 0.09 -

Nxera Pharma Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.34

Competitive Comparison of Nxera Pharma Co's Capex-to-Operating-Income

For the Biotechnology subindustry, Nxera Pharma Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nxera Pharma Co's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's Capex-to-Operating-Income falls into.



Nxera Pharma Co Capex-to-Operating-Income Calculation

Nxera Pharma Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-851) / -9526
=N/A

Nxera Pharma Co's Capex-to-Operating-Income for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-56) / -578
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nxera Pharma Co  (TSE:4565) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Nxera Pharma Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Nxera Pharma Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Nxera Pharma Co Business Description

Traded in Other Exchanges
Address
Midtown East, 9-7-2 Akasaka Minato-ku, Tokyo, JPN, 107-0052
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).

Nxera Pharma Co Headlines

No Headlines